Cardiomyopathy Trial, Recruiting NCT07344480 Sponsor: Deutsches Herzzentrum Muenchen Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT07344480
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed through genetic testing with a RASopathy (a group of conditions caused by changes in a specific set of genes that affect how cells grow and communicate)
  • A heart scan (echocardiogram) has shown that the walls of your heart are thicker than normal, with or without a blockage in the heart's outflow
  • You were admitted to hospital between 1 January 2015 and 30 June 2019 because of heart failure, OR you developed worsening heart failure during any hospital stay within your first 6 months of life

Who may not be able to join:

  • You are currently taking a type of medication called an mTOR inhibitor or a MEK inhibitor (specific drugs that target certain cell signalling pathways — check with the trial site if you are unsure whether your medication falls into these categories)
  • It is not possible to find or work out your heart failure severity score (called a "Ross Score") from your medical records from when you were in the first 6 months of life

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 89 1218-2441

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Deutsches Herzzentrum Muenchen
Registry
ClinicalTrials.gov
Start date
17 June 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

To define the one-year transplant-free survival rate of patients with infantile-onset RASopathy-associated hypertrophic cardiomyopathy, admitted to the hospital with congestive heart failure by 6 months of age.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov